Equilis Te

RSS

Adjuvanted vaccine against tetanus

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 30/09/2016

Authorisation details

Product details
Name
Equilis Te
Agency product number
EMEA/V/C/000093
Active substance
tetanus toxoid
International non-proprietary name (INN) or common name
Adjuvanted vaccine against tetanus
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI05AB03
Publication details
Marketing-authorisation holder
Intervet International BV
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
08/07/2005
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

20/09/2016 Equilis Te - EMEA/V/C/000093 - IA/007/G

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

IMMUNOLOGICALS FOR EQUIDAE

Therapeutic indication

Active immunisation of horses from 6 months of age against tetanus to prevent mortality.

Onset of immunity: 2 weeks after the primary vaccination course

Duration of immunity: 17 months after the primary vaccination course, 24 months after the first revaccination

Assessment history

How useful was this page?

Add your rating